These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30605414)

  • 1. Application of PCSK9 Inhibitors in Practice.
    Kaufman TM; Warden BA; Minnier J; Miles JR; Duell PB; Purnell JQ; Wojcik C; Fazio S; Shapiro MD
    Circ Res; 2019 Jan; 124(1):32-37. PubMed ID: 30605414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B; Jubran A
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
    Davis LE; Pogge EK
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions.
    Doshi JA; Li P; Puckett JT; Pettit AR; Raman S; Parmacek MS; Rader DJ
    Value Health; 2020 Feb; 23(2):209-216. PubMed ID: 32113626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes.
    Myers KD; Farboodi N; Mwamburi M; Howard W; Staszak D; Gidding S; Baum SJ; Wilemon K; Rader DJ
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005404. PubMed ID: 31331194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers.
    Doshi JA; Puckett JT; Parmacek MS; Rader DJ
    Circ Cardiovasc Qual Outcomes; 2018 Jan; 11(1):e003939. PubMed ID: 29326146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
    Navar AM; Taylor B; Mulder H; Fievitz E; Monda KL; Fievitz A; Maya JF; López JAG; Peterson ED
    JAMA Cardiol; 2017 Nov; 2(11):1217-1225. PubMed ID: 28973087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
    Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
    Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
    J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia.
    White CM
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):301-308. PubMed ID: 29649884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
    Chamberlain AM; Gong Y; Shaw KM; Bian J; Song WL; Linton MF; Fonseca V; Price-Haywood E; Guhl E; King JB; Shah RU; Puro J; Shenkman E; Pawloski PA; Margolis KL; Hernandez AF; Cooper-DeHoff RM
    J Am Heart Assoc; 2019 May; 8(9):e011246. PubMed ID: 31020929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 inhibitors in clinical practice: Delivering on the promise?
    Stoekenbroek RM; Hartgers ML; Rutte R; de Wijer DD; Stroes ESG; Hovingh GK
    Atherosclerosis; 2018 Mar; 270():205-210. PubMed ID: 29254691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort.
    Dressel A; Schmidt B; Schmidt N; Laufs U; Fath F; Chapman MJ; Grammer TB; März W
    Vascul Pharmacol; 2019 Sep; 120():106566. PubMed ID: 31207358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
    Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
    Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.
    Virani SS; Akeroyd JM; Nambi V; Michos ED; Morris PB; Nasir K; Smith SC; Stone NJ; Petersen LA; Ballantyne CM
    Circulation; 2019 Jan; 139(3):410-412. PubMed ID: 30586689
    [No Abstract]   [Full Text] [Related]  

  • 20. PCSK9 inhibitor valuation: A science-based review of the two recent models.
    Baum SJ; Cannon CP
    Clin Cardiol; 2018 Apr; 41(4):544-550. PubMed ID: 29512936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.